Perampanel is a selective, noncompetitive AMPA receptor antagonist with demonstrated efficacy and tolerability in partial seizures in patients aged ≥12 years in Phase III studies. Post-hoc analysis of these studies was conducted to determine the efficacy and tolerability of perampanel based on the number of concomitant antiepileptic drugs (AEDs) at baseline, as well as to examine which baseline characteristics, if any, were predictors of efficacy. Efficacy parameters were based on the number of baseline AEDs, and logistic regression analyses were used to evaluate the association of demographic and baseline clinical factors with probability of ≥50% reduction in seizure frequency. Patients on 1 AED at baseline were significantly more likely to have reduced seizure frequency (P < 0.02) and improved 50% responder rate (P < 0.02) than patients on 3 AEDs at baseline. Secondarily generalized seizures at baseline, unknown etiology, and use of concomitant non-inducer AEDs were also established as positive predictors of efficacy (50% responder rate; P < 0.01). Patients with more AEDs at baseline were associated with greater use of inducers (P < 0.01), which may result in decreased exposure of perampanel in these patients and lower efficacy. Patients with 1 AED at baseline had a significantly shorter time since diagnosis compared with patients in the 3 (P < 0.01) AEDs group, as well as a lower median seizure frequency at baseline compared to patients on 3 AEDs (P < 0.05), suggesting that the reduced efficacy of perampanel with 3 AEDs may also be associated with the greater severity of seizures in the patient groups. The incidence of adverse events in perampanel-treated patients was similar regardless of the number of AEDs at baseline. Greater efficacy is predicted for patients receiving fewer concomitant AEDs when starting perampanel, as well as for those receiving concomitant treatment with AEDs that are not CYP3A4 enzyme-inducers, compared to patients treated with multiple concomitant AEDs. The results of this study provide additional information for clinicians considering adding perampanel to their patients' treatment regimen earlier rather than later, and offer evidence regarding the potential for increased efficacy with a decreased medication burden.
Introduction
Perampanel, a first-in-class antiepileptic drug (AED), is approved for adjunctive treatment of partial seizures with or without secondarily generalized seizures and for primary generalized tonic-clonic seizures in patients aged 12 years or older with epilepsy (FYCOMPA US Prescribing Information, 2015; Rektor, 2013) . Perampanel is a selective, noncompetitive AMPA receptor antagonist and has demonstrated efficacy and tolerability in patients aged ≥12 years with partial seizures in 3 multicenter, double-blind, randomized, placebo-controlled, Phase III studies, with patients taking stable doses of up to 3 approved AEDs (French et al., , 2013 Krauss et al., 2012) . Although perampanel has not been shown to meaningfully affect the plasma concentrations of concomitant AEDs, data from population pharmacokinetic analyses in clinical studies indicate that co-administration of the CYP3A4 enzyme-inducing AEDs carbamazepine, oxcarbazepine, and phenytoin affects the metabolism of perampanel and results in lower plasma concentrations (Brodie et al., 2013; Fuseau et al., 2011; Gidal et al., 2013; Krauss et al., 2012) .
There are over 20 different AEDs available for treatment of epilepsy, a common neurological disease (Fisher et al., 2014; French, 2007; Loscher and Schmidt, 2011 ) that affects more than 65 million people worldwide (Institute of Medicine of the National Academies, 2012) . Approximately half of these treatments have been developed within the last 15 years (French, 2007) , and the newer generation AEDs offer more favorable pharmacokinetics, better tolerability, and improved drug interaction profiles than those developed previously (Bialer, 2012; Verrotti et al., 2011) . This range of options allows physicians to tailor treatment for each individual patient (Bialer, 2012; Franco et al., 2013) . However, despite these advances in antiepileptic treatments, patient outcomes still remain poor (Loscher and Schmidt, 2011; French, 2007) . Approximately 30% of patients with epilepsy are still resistant to drug treatment (Brodie, 2010; French, 2007; Perucca et al., 2007) , as defined by a failure of at least 2 adequate trials of AEDs (Kwan et al., 2010) . In addition to the uncontrolled seizures, there is a higher incidence of physical, mental, and social adverse outcomes in patients who fail to achieve seizure freedom with the first prescribed AED (Perucca et al., 2011) .
The inability to identify which patients will respond to treatment (have fewer seizures or become seizure free) can lead to a "trial-and-error" approach in prescribing drugs and other therapies that may be less than optimal (FDA, 2013) . Because there is a wide variation in the effectiveness and safety profile of current AEDs, it is important for physicians to consider developing personalized AED therapy for patients with epilepsy and distinguish those patients most likely to benefit from a given treatment (FDA, 2013) , especially since many patients are drug-resistant. This "precision medicine" targets both AED efficacy and safety to ensure that patients get the right treatment. In order to optimize AED therapy and provide precision medicine to patients with epilepsy, it is important to consider the genetics and medical history of the individual, as well as the concomitant AEDs they are receiving (Depondt, 2008; Robinson, 2012; Walker et al., 2014) . Rational polytherapy of AED combinations with differing mechanisms of action can be an option for drug-resistant patients to help control seizures and achieve seizure freedom with minimal impact on quality of life (French and Faught, 2009; St Louis, 2009 ). The concept of rational polytherapy suggests that the combination of drugs with different mechanisms of action is more likely to have additive antiepileptic effects and produce seizure freedom (Barker-Haliski et al., 2014; Brodie and Sills, 2011; French and Faught, 2009; St Louis, 2009 ). This report aims to explore patient baseline characteristics to determine potential predictors of perampanel's efficacy. Specifically, this study examines the efficacy and tolerability of perampanel based on the number of concomitant AEDs at baseline in a post hoc analysis of the 3 Phase III perampanel clinical studies.
Methods

Study design and patients
The 3 Phase III studies (study 304, NCT00699972; study 305, NCT00699582; and study 306, NCT00700310) were conducted between April 2008 and January 2011 in more than 40 countries. All studies were conducted in accordance with the Helsinki Declaration, European Medicines Agency requirements, and the US Code of Federal Regulations, as appropriate. Study protocols, amendments, and informed consents were reviewed by national regulatory authorities in each country and by independent ethics committees or institutional review boards for each site. Prior to participation, all patients provided written informed consent (French et al., , 2013 Krauss et al., 2012; Steinhoff et al., 2013) .
These studies, described in detail elsewhere, included a 6-week baseline period, a 19-week double-blind treatment phase (a 6-week titration period followed by a 13-week maintenance period), and a 4-week follow-up period or continuation in the open-label extension study. In all 3 studies, patients entered the pre-randomization phase and were assessed for baseline seizure frequency and eligibility for the 19-week, double-blind treatment phase. Eligible patients included those aged ≥12 years diagnosed with partial seizures with or without secondary generalization in accordance with the 1981 International League Against Epilepsy Classification of Epileptic Seizures (International League Against Epilepsy, 1981) , and who had experienced ≥2 AED failures and had ≥5 partial seizures during baseline. Patients were required to have been on a stable dose of any concomitant benzodiazepines (French et al., 2013) . Patients had to have been on stable doses of 1 to 3 approved AEDs for at least 21 days prior to pre-randomization (French et al., , 2013 Krauss et al., 2012) . Of the 3 AEDs, patients were allowed one CYP3A4 enzyme-inducing AED, defined as carbamazepine, phenytoin, phenobarbital, or primidone at the time of enrollment. Later analysis of the plasma concentration of perampanel and pharmacokinetic modeling of the pooled data from the Phase III studies showed that carbamazepine, oxcarbazepine, and phenytoin were the clinically important inducers of perampanel metabolism. In this current analysis, carbamazepine, oxcarbazepine, and phenytoin are defined as perampanel CYP3A4 inducers (Brodie et al., 2013; Gidal et al., 2013; Hussein et al., 2011 Hussein et al., , 2012 .
Following the 6-week baseline period, patients were randomized to placebo or perampanel doses of 2, 4, 8 or 12/mg day (French et al., , 2013 Krauss et al., 2012) . During the 6-week titration period, perampanel doses were increased by 2 mg/day/week until the randomized dose or intolerability was reached. Dose reduction was permitted at the investigators' discretion for patients experiencing intolerable adverse events, but more than one 2-mg down-titration at a time was discouraged. If tolerability later improved, up-titration was allowed in these patients. During the 13-week maintenance period, patients continued on the dose achieved during titration and continued to receive their established concomitant AEDs without modification. Those who discontinued treatment or who did not enter the extension study had a followup visit 4 weeks after the end of therapy (French et al., , 2013 Krauss et al., 2012) .
Measurement of efficacy
Efficacy was determined based on the pooled population of patients from the three Phase III studies and on the number of baseline concomitant AEDs taken by patients. Patients recorded seizure frequency and type in daily diaries. Efficacy endpoints included median percent decrease in total seizure frequency per 28 days of treatment during the double-blind period relative to the prerandomization phase baseline, 50% responder rate (defined as the percentage of patients who experienced a ≥50% reduction from baseline in seizure frequency per 28 days of treatment during the maintenance period with last observation carried forward), and achievement of seizure-free status.
Tolerability
Tolerability was assessed based on number of baseline AEDs and included incidence rates of treatment-emergent adverse events (TEAEs), treatment-related TEAEs, treatment-emergent serious adverse events (SAEs), and TEAEs leading to study withdrawal.
Statistical analysis
The distribution of etiology in patients with different numbers of baseline AEDs was compared using Cochran-Mantel-Haenszel statistics. Time since diagnosis of epilepsy in the three different AED groups was compared using a least squares regression model. The baseline seizure rate in these three AED groups was compared using a least squares regression model based on ranks. All the comparisons were adjusted for treatment group.
To assess the association between efficacy and the number of baseline AEDs, the three efficacy measures (i.e., median percent decrease in seizure frequency, 50% responder rate, and seizurefree status) were reported separately for each AED group. In order to assess the impact of number of AEDs at baseline on seizure frequency efficacy endpoints, an analysis of covariance on the ranktransformed data (rank ANCOVA) model was used to pair-wise compare AED groups (1 AED vs 2 AEDs, 1 AED vs 3 AEDs, and 2 AEDs vs 3 AEDs). First, the baseline seizure frequency per 28 days and the percentage change per 28 days during treatment were rank-transformed separately. A rank ANCOVA was then conducted with treatment, AED groups and the ranked baseline seizure frequency per 28 days as covariates. A P value ≤0.05 was considered statistically significant.
A Cochran-Mantel-Haenszel test adjusted by treatment was used to compare the proportion of seizure-free status among the 3 AED groups.
For the analyses on factors predictive of efficacy, logistic regression analyses were used to evaluate the association between demographic and baseline clinical factors with 50% responder rate. Because the 50% responder rate is most clinically useful for physicians, it was selected as the efficacy outcome measure for the logistic regression analyses. Separate logistic regression modeling was conducted on each baseline variable [age, gender, race, ethnicity, weight, height, body mass index (BMI), time since diagnosis, etiology, epileptogenic region, seizure type, number of AEDs at baseline, and non-inducer vs inducer concomitant AEDs (inducers included carbamazepine, oxcarbazepine, or phenytoin)], controlling for treatment group, region, and baseline seizure rate. Factors in these separate models with a P value <0.05 were included in a final multivariate logistic regression model.
Results
Patient demographics and baseline characteristics
Based on the pooled analysis of the 3 Phase III studies, 1478 patients were included in the efficacy analysis and 1480 patients were included in the tolerability analyses. At baseline, 206 (13.9%), 749 (50.7%), and 523 (35.4%) patients were on 1, 2, or 3 AEDs, respectively, and were included in this analysis (Table 1) . Age, sex, and seizure type (complex partial or secondarily generalized seizures) were not different between placebo and the perampanel treatment groups (Table 1) .
Controlling for the treatment group, etiology was not significantly different across baseline AED groups (P > 0.05) and for most patients, etiology was unknown [n = 104 (50.5%), 1 AED; n = 376 (50.2%), 2 AEDs; n = 236 (45.1%), 3 AEDs]. The etiologies of structural brain anomalies/malformations, other causes, head injury/cranial trauma and central nervous system (CNS) infections were also reported in patients (>5% of patients for each etiology) and were similar in patients regardless of the number of AEDs at baseline.
Controlling for the treatment group, a longer time since diagnosis was associated with a greater number of AEDs at baseline (Table 1) . For the total population (perampanel and placebo groups), the time since diagnosis was significantly shorter with 1 AED (18.9 years) compared to either 2 or 3 AEDs (21.1 years and 21.9 years, respectively; P < 0.05 for 1 vs 2 AEDs and P < 0.01 for 1 vs 3 AEDs).
Carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, topiramate, and valproic acid were the most common coadministered AEDs at baseline [≥10% of patients in the total population (perampanel and placebo groups)] in all Phase III studies. As shown in Table 2 , use of the CYP3A4 enzyme-inducing AEDs carbamazepine, oxcarbazepine, or phenytoin was increasingly higher with more AEDs at baseline (P < 0.01).
The median rate of seizures at baseline for the total population was significantly higher in patients from the 3-AEDs group compared with patients in the 1-or 2-AED groups (14.0 vs 9.7 and 10.8, respectively; P < 0.05).
Efficacy
Percent decrease in seizure frequency
The median percent decrease in seizure frequency over 28 days during the double-blind phase relative to baseline was greater for patients taking 1 AED at baseline compared to patients receiving 3 AEDs (P < 0.02). A significant difference was not observed between patients taking 1 vs 2 AEDs (P = 0.06) and 2 vs 3 AEDs (P = 0.28) at baseline. As shown in Fig. 1A , median percent decrease in seizure frequency relative to baseline was greater for patients taking 1 AED at baseline compared to 3 AEDs in all perampanel treatment groups. For patients receiving 2 mg of perampanel, the median percent decrease in seizure frequency was greater for those taking 1 AED at baseline (20.6%) compared to the respective placebo group (12.5%), whereas patients taking 2 or 3 AEDs at baseline had results similar to the respective groups receiving placebo. Median percent decrease in seizure frequency for the placebo-treated patients was similar among the three AED groups (Fig. 1A) .
50% responder rate
Patients taking 1 AED at baseline had a significantly higher 50% responder rate compared to those taking 3 AEDs at baseline (P < 0.02). The 50% responder rate was higher in patients receiving 8 mg and 12 mg compared to placebo, irrespective of the number of AEDs at baseline (Fig. 1B) .
Seizure-free status
For all perampanel-and placebo-treated patients who completed the double-blind study, the highest percentages of patients achieving seizure-free status during the maintenance phase were among those taking 1 AED at baseline, except for the 2 mg perampanel group, in which no one with only 1 concomitant AED achieved seizure-free status. Overall, patients receiving 4 mg, 8 mg, and 12 mg of perampanel had higher percentages achieving seizurefree status (ranging from 2.5% to 12.5% of patients) compared to patients receiving placebo (ranging from 0.7% to 2.0%) and 2 mg perampanel (ranging from 0% to 2.9%), regardless of number of baseline AEDs (Fig. 1C) . No statistically significant difference among the three AEDs groups was observed for the proportion of patients with seizure-free status (P > 0.2). This may be due to the overall small number of patients completing the study and achieving seizure-free status (Fig. 1C) .
Logistic regression analysis data
To evaluate the association of demographic and baseline clinical factors with the probability of ≥50% reduction in seizure frequency, logistic regression analyses were conducted. Overall, 4 variables were identified as baseline predictors for improved efficacy (Table 3) . Fewer AEDs at baseline was a predictor of perampanel efficacy in that patients on 1 AED at baseline were significantly more likely to have improved efficacy (50% responder rate) than patients on 3 AEDs (P < 0.02).
Patients with secondarily generalized seizures at baseline were associated with improved efficacy compared to those without secondarily generalized seizures (P < 0.01). Patients with unknown etiology at baseline were more likely to be responders than those with CNS infection etiology (P < 0.01). Additionally, patients using non-enzyme-inducing AEDs at baseline were more likely to be responders compared to those taking CYP3A4 enzyme-inducing AEDs carbamazepine, oxcarbazepine, or phenytoin (P < 0.01).
Tolerability
Incidence of any TEAEs was similar regardless of the number of AEDs at baseline in the total perampanel population (77.4%, 76.7%, and 77.1% for 1, 2, and 3 AEDs, respectively). A similar result was found in the placebo group (61.7%, 64.7%, and 70.7% for 1, 2, and 3 AEDs, respectively). As reported in previous publications on the three individual Phase III studies (French et al., , 2013 Krauss et al., 2012) , the most common TEAEs included dizziness, somnolence, headache, fatigue, and irritability, which were found in all AED groups. The TEAEs of fall and upper respiratory tract infection were observed at a rate of ≥5% only in total perampaneltreated patients on 3 AEDs at baseline (6.1% and 5.0% respectively), and at a lower rate in placebo-treated groups (3.7% for each). For treatment-related TEAEs, treatment-emergent SAEs, or TEAEs leading to perampanel withdrawal, there was no notable difference across baseline AED groups in the total perampanel group. Patients treated with perampanel 8 mg and 12 mg had a higher incidence of treatment-related TEAEs compared to placebo, regardless of the number of AEDs at baseline. No deaths occurred in any treatment group.
Discussion
Precision medicine aims to offer treatment for epilepsy by classifying patients into subsets with a common biological basis of the disease, such as genetics or medical history (Robinson, 2012) . This individualized treatment aims at determining which patients will respond best to an AED treatment, including perampanel, with few b During the maintenance phase (last observation carried forward). c n, patients who completed the maintenance phase with seizure-free status; percentages are based on completer set. AED = antiepileptic drug. Other predictors of efficacy were presence of secondarily generalized seizures, unknown etiology at baseline, and non-inducer concomitant AED use. Furthermore, there were no differences in perampanel tolerability outcomes based on the number of concomitant AEDs.
Although monotherapy is recommended for the treatment of epilepsy, a mechanism-of-action-based AED polytherapy can be an option for drug-resistant patients to help control seizures (St Louis, 2009) . Indeed, the patients enrolled in the perampanel Phase III clinical trials had already experienced at least 2 AED treatment failures and were on a stable dose of 1 to 3 AEDs (French et al., , 2013 Krauss et al., 2012) . The reduced efficacy of perampanel in patients taking 3 AEDs compared to 1 AED may be associated with the greater severity of seizures in the patient groups. For example, patients with 3 AEDs at baseline had a significantly longer time since diagnosis (21.9 years) as well as a higher median seizure frequency per 28 days at baseline (14.0) compared with patients in the 1 AED group (18.9 years and 9.7 per 28 days, respectively). Previous research has shown that higher seizure frequency can indicate drug-resistant epilepsy (Kwan and Brodie, 2000) . Patients with drug-resistant epilepsy often try a number of different AEDs without gaining adequate seizure control and are therefore less likely to respond to subsequent treatment (Brodie, 2010; Kwan and Brodie, 2000; Luciano and Shorvon, 2007) .
The reduced efficacy of perampanel in patients with 3 concomitant AEDs at baseline may also be explained by their association with more prevalent use of the CYP3A4 enzyme-inducing concomitant AEDs carbamazepine, oxcarbazepine, and phenytoin. Perampanel is extensively metabolized through primary oxidation, which is mediated predominantly by CYP3A4 and CYP3A5 (Rogawski and Hanada, 2013 ). An analysis of Phase I pharmacokinetic drug interaction studies showed a 3-fold increase in the clearance of perampanel in the presence of the enzyme-inducing AED carbamazepine. Additionally, a Phase II pharmacokinetics/pharmacodynamics study with perampanel showed that, over a period of 20 weeks, exposure to perampanel was 2-fold lower in patients co-administered AEDs that were strong CYP450 enzyme inducers than in patients not receiving inducers (Fuseau et al., 2011) . Data from the controlled Phase III studies were analyzed in a population pharmacokinetic model that showed that clearance of perampanel was significantly increased by 2-to 3-fold in the presence of the CYP3A4 inducers carbamazepine, oxcarbazepine, and phenytoin, resulting in lower exposure to perampanel (Brodie et al., 2013; Gidal et al., 2013) . These data indicate that perampanel efficacy may be lowered as a result of increased clearance when added to a treatment regimen containing carbamazepine, oxcarbazepine, and phenytoin. Consequently, the dose of perampanel may need to be monitored and adjusted when administered concomitantly with these treatments (FYCOMPA US Prescribing Information, 2015) .
The tolerability of perampanel was not notably affected by the number of AEDs at baseline. Indeed, the rates of any TEAEs, regardless of number of concomitant AEDs at baseline, was similar to those reported in the Phase III studies (French et al., , 2013 Krauss et al., 2012) . Falls and upper respiratory tract infection were reported only in the patient group on 3 AEDs at baseline for both perampanel-and placebo-treated patients. This finding of falls is supported by a study by Petty and colleagues, which demonstrated that both AED polytherapy (>1 AED) and longer duration of AED use were independent predictors of increased sway (impaired balance performance); however, the exact number of AEDs used was not specified in the study (Petty et al., 2010) . Overall, the incidence of TEAEs, treatment-related TEAEs, treatment-emergent SAEs, and TEAEs leading to perampanel withdrawal was similar across baseline AED groups.
Conclusions
Patients receiving fewer concomitant AEDs when starting perampanel, or those receiving concomitant treatment with AEDs that are not CYP3A4 enzyme-inducers, show an improved response with perampanel compared to those patients treated with multiple AEDs. These data provide important information for clinicians when considering adding perampanel to a patient's treatment flow and offers evidence on the potential for increased efficacy with decreased medication burden. Understanding drug interactions and the patient profile is important for the treatment management of epilepsy in order to control seizures and avoid treatment-related adverse events (St Louis, 2009 ). Perampanel dosing should be based on clinical response and tolerability (FYCOMPA US Prescribing Information, 2015) in order to provide adequate, individualized seizure control.
Disclosures
T Glauser is funded by NIH grants 2U01-NS045911, U10-NS077311, R01-NS053998, R01-NS062756, R01-NS043209, R01-LM011124, and R01-NS065840. He has received consulting fees from Supernus, Sunovion, Eisai, UCB, Lundbeck, and Questcor. He also serves as an expert consultant for the US Department of Justice and Eisai; and has received compensation for this work as an expert on medico-legal cases. He receives royalties from a patent license from AssureRx Health.
A Laurenza, H Yang, B Williams, T Ma, and R Fain are employees of Eisai Inc.
